Table 3.

Primary Analysis: Relative risks of Sudden Arrhythmic Death during Follow-up, According to Log-transformed Continuous values or Pre-specified Threshold levels of NT-proBNP and hsCRP.

Biomarker	RR (95% CI) per 1-SD in Log Variable	P-value	RR (95%CI) for values above the 80^th percentile	P-value	RR (95%CI) for Clinical Cut-Points^*	P-value
NT-proBNP
Model 1 (age, fasting) ^†	1.32 (1.01 – 1.71)	0.04	1.50 (0.83 – 2.71)	0.18	3.60 (1.43 – 9.10)	0.007
Multivariable Model 2^‡	1.45 (1.07 – 1.97)	0.02	1.77 (0.88 – 3.55)	0.11	5.45 (1.77 –16.8)	0.003
Multivariate Model 3^§	1.49 (1.09 –2.05)	0.01	1.99 (0.97 – 4.12)	0.06	5.68 (1.78 –18.2)	0.003
hsCRP
Model 1 (age, fasting) ^†	1.33 (1.03 – 1.70)	0.03	1.57 (0.92 – 2.68)	0.10	1.40 (0..87–2.24)	0.17
Multivariate Model 2^†	1.18 (0.87 – 1.59)	0.28	1.39 (0.74 – 2.61)	0.33	1.12 (0.65–1.94)	0.69
Multivariate Model 3 ^§	1.17 (0.85 – 1.61)	0.34	1.49 (0.76 – 2.93)	0.25	1.05 (0.58–1.91)	0.86

hsCRP (>3.0 mg per liter)²³ and NT-pro-BNP (≥ 389 pg/mL)²⁴.

^†

Model 1: Controlled simultaneously for age and fasting status

^‡

Multivariable Model 2: Controlled for variables listed above in Model 1 and history of hypertension, history of diabetes, alcohol consumption (<0.1 g, 0.1–14.9, 15.0 to 29.9, 30+), parental history of myocardial infarction prior to age 60, body-massindex (<25 kg/m², 25–30 kg/m², >=30 kg/m²), physical activity (quintiles of metabolic equivalent (MET-hours)), current postmenopausal hormone use, GFR, and aspirin use>=22 days/month. ^‡Multivariate

^§

Model 3: Controlled for variables listed above in multivariable Model 2 and simultaneously for triglycerides, TC/HDL-Ratio, and for NTproBNP or hsCRP.